Thanks, but the assignee is Flaskworks whose patent interests are now owned by NWBO. Neon therapeutics was never an assignee and Neon therapeutics almost immediately scrapped their dendritic cell program before it began. I believe NEON therapeutics is now defunct, but I did see a picture of James Allison and LP intently discussing something of interest at a prior ASCO a few years back. :-)
The end to end adaptability of the Baton system can allow adaptations to side by side biologics like lysate, DCs and monoclonal antibodies. I don’t have time right now to explain why L is just as logical, or perhaps more logical to use than Direct in this system, but ultimately the system can scale both and/or combinations imho.
News 
Market Data 
Discover 
